letrozole and Carcinoma, Ductal, Breast studies

Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.

Research Excerpts

Excerpt	Relevance	Reference
"Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole."	9.34	Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020)
"A total of 119 postmenopausal women with ER-positive, HER2-negative operable breast cancer were assigned to four months of neoadjuvant letrozole before definitive surgery."	9.27	Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). ( Christiansen, P; Ejlertsen, B; Grundtmann, B; Handler, J; Jensen, MB; Knoop, AS; Laenkholm, AV; Rasmussen, BB; Skriver, SK; Tvedskov, TF, 2018)
" Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy."	8.02	Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021)
" She was diagnosed with right locally advanced breast cancer (cT4bN2aM0, stageIIIB) and received hormone therapy with letrozole."	7.78	[A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole]. ( Hibino, M; Nakamura, M; Okuyama, M; Sasaki, Y; Tenma, K, 2012)
" We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology."	7.77	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011)
"We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole."	7.76	[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010)
"The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen."	7.76	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010)
"The British Columbia Breast Cancer Outcomes database was used to identify women aged 45 years or older at the time of diagnosis with early-stage (I-IIIA) breast cancer who received tamoxifen and were disease free 5 years after diagnosis."	7.74	Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007)
"We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors."	6.82	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016)
"Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97."	6.80	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. ( Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G, 2015)
"Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2."	6.76	[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011)
"Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67."	6.73	Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008)
"We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab."	5.48	[A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole]. ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E, 2018)
"Therefore, advanced breast cancer with left-sided pleural effusion and metastases to the pleura and bone was diagnosed."	5.39	[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report]. ( Nakamura, H; Yoneyama, K, 2013)
"After 3 months, the metastases showed a notable response, which was subsequently maintained for 19 months."	5.37	[A case of secondary inflammatory breast cancer with multiple metastases in which operation was possible through letrozole monotherapy]. ( Kusama, M, 2011)
"Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole."	5.34	Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020)
"A total of 119 postmenopausal women with ER-positive, HER2-negative operable breast cancer were assigned to four months of neoadjuvant letrozole before definitive surgery."	5.27	Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). ( Christiansen, P; Ejlertsen, B; Grundtmann, B; Handler, J; Jensen, MB; Knoop, AS; Laenkholm, AV; Rasmussen, BB; Skriver, SK; Tvedskov, TF, 2018)
"Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence."	5.27	Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE, 2018)
"One hundred fifteen postmenopausal women with >2 cm, estrogen receptor (ER) or progesterone receptor (PgR)-positive breast cancer were enrolled in a trial of 16 to 24 weeks of letrozole 2."	5.14	Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. ( Bae, K; Budd, GT; Carey, LA; Commean, P; Ellis, MJ; Esserman, LJ; Fleming, GF; Giuntoli, T; Harris, LA; Leight, GS; Luo, J; Marcom, PK; Olson, JA, 2009)
"Postmenopausal women with hormone-sensitive breast cancer were given three months of letrozole 2."	5.13	Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. ( Chow, LW; Loo, WT; Toi, M; Yip, AY, 2008)
" Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer."	5.05	Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. ( Nazarian, RM; Russell-Goldman, E, 2020)
" Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy."	4.02	Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021)
"Subcutaneous testosterone-letrozole was an effective treatment for this patient's breast cancer and did not interfere with chemotherapy."	3.85	Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications. ( Dimitrakakis, C; Glaser, RL; York, AE, 2017)
"Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer."	3.80	Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014)
" She was diagnosed with right locally advanced breast cancer (cT4bN2aM0, stageIIIB) and received hormone therapy with letrozole."	3.78	[A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole]. ( Hibino, M; Nakamura, M; Okuyama, M; Sasaki, Y; Tenma, K, 2012)
" We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology."	3.77	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011)
"We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole."	3.76	[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010)
"The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen."	3.76	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010)
"The British Columbia Breast Cancer Outcomes database was used to identify women aged 45 years or older at the time of diagnosis with early-stage (I-IIIA) breast cancer who received tamoxifen and were disease free 5 years after diagnosis."	3.74	Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007)
"We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors."	2.82	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016)
"Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97."	2.80	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. ( Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G, 2015)
"However, not all breast cancer patients respond to aromatase inhibitors (AI), and many patients become unresponsive or relapse."	2.76	Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. ( Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC, 2011)
"Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2."	2.76	[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011)
"Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67."	2.73	Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008)
"Treatment of male breast cancer is typically extrapolated from data on the treatment of female breast cancer."	2.43	Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. ( Meterissian, SH; Zabolotny, BP; Zalai, CV, 2005)
"We present a 71-year-old lady with diplopia, restricted eye movements, suppressed thyroid-stimulating hormone and enlargement of all extraocular muscles while on thyroxine replacement for hypothyroidism."	1.51	Paraneoplastic syndrome - a rare but treatable cause of non-thyroid-related extraocular muscle enlargement. ( Diamond, T; Kumar, S, 2019)
"We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab."	1.48	[A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole]. ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E, 2018)
"Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor."	1.43	[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole]. ( Yamamoto, C; Yamamoto, D; Yamamoto, M, 2016)
"Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined."	1.42	Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015)
"The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown."	1.39	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013)
"Therefore, advanced breast cancer with left-sided pleural effusion and metastases to the pleura and bone was diagnosed."	1.39	[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report]. ( Nakamura, H; Yoneyama, K, 2013)
"Seventy-two patients with breast cancer who failed chemotherapy were treated at the Tumor Hospital of Harbin Medical University from January 2001 to January 2012."	1.39	[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy]. ( Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP, 2013)
"The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008."	1.38	Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012)
"The median interval from diagnosis of breast cancer was 57 months (range: 11 - 189 mo)."	1.38	[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis]. ( Cai, RG; Fan, Y; Li, J; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2012)
"After 3 months, the metastases showed a notable response, which was subsequently maintained for 19 months."	1.37	[A case of secondary inflammatory breast cancer with multiple metastases in which operation was possible through letrozole monotherapy]. ( Kusama, M, 2011)
"In patients with breast cancer and co-existing pleural effusions, ascites and adnexal masses, the probability of disseminated disease is high."	1.35	A case of Meigs syndrome mimicking metastatic breast carcinoma. ( Al Mufti, R; Behranwala, K; Hadjiminas, DJ; Lanitis, S; Sivakumar, S; Zacharakis, E, 2009)

Research

Studies (50)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Clinical Benefit Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (20.00)	29.6817
2010's	36 (72.00)	24.3611
2020's	4 (8.00)	2.80

Authors	Studies
Russell-Goldman, E	1
Nazarian, RM	1
Lazzeroni, M	1
DeCensi, A	1
Skriver, SK	2
Jensen, MB	3
Knoop, AS	2
Ejlertsen, B	5
Laenkholm, AV	2
Jung, SU	1
Jung, M	1
Choi, JH	1
Jeon, CW	1
Blok, EJ	1
Kroep, JR	1
Meershoek-Klein Kranenbarg, E	1
Duijm-de Carpentier, M	1
Putter, H	1
van den Bosch, J	1
Maartense, E	1
van Leeuwen-Stok, AE	1
Liefers, GJ	1
Nortier, JWR	1
Rutgers, EJT	1
van de Velde, CJH	1
Youngwirth, LM	1
Boughey, JC	1
Hwang, ES	1
Rasmussen, BB	2
Handler, J	1
Grundtmann, B	1
Tvedskov, TF	1
Christiansen, P	1
Lykkesfeldt, AE	1
Iversen, BR	1
Giobbie-Hurder, A	3
Reiter, BE	1
Kirkegaard, T	1
Hara, Y	1
Sakurai, K	1
Adachi, K	1
Fujiwara, A	1
Ono, Y	1
Waga, E	1
Hirano, T	1
Enomoto, K	1
Kumar, S	1
Diamond, T	1
Guarneri, V	1
Dieci, MV	1
Bisagni, G	1
Frassoldati, A	1
Bianchi, GV	1
De Salvo, GL	1
Orvieto, E	1
Urso, L	1
Pascual, T	1
Paré, L	1
Galván, P	1
Ambroggi, M	1
Giorgi, CA	1
Moretti, G	1
Griguolo, G	1
Vicini, R	1
Prat, A	1
Conte, PF	1
Hwang, CK	1
Ma, L	1
Sen, HN	1
Di Lauro, L	1
Vici, P	1
Del Medico, P	1
Laudadio, L	1
Tomao, S	1
Giannarelli, D	1
Pizzuti, L	1
Sergi, D	1
Barba, M	1
Maugeri-Saccà, M	1
Yoneyama, K	1
Nakamura, H	1
Nie, D	1
You, QS	1
Luan, JW	1
Li, Y	1
Li, XL	1
Guo, RT	1
Zhang, LP	1
Wu, J	1
Foster, LM	1
Mahoney, ME	1
Harmon, MW	1
Allen, JW	1
Luh, JY	1
Grassadonia, A	1
Di Nicola, M	1
Grossi, S	1
Noccioli, P	1
Tavoletta, S	1
Politi, R	1
Angelucci, D	1
Marinelli, C	1
Zilli, M	1
Ausili Cefaro, G	1
Tinari, N	1
De Tursi, M	1
Iezzi, L	1
Cioffi, P	1
Iacobelli, S	1
Natoli, C	1
Cianchetti, E	1
Pagano, M	1
Asensio, SN	1
Zanelli, F	1
Lococo, F	1
Cavazza, A	1
Damiani, S	1
Rapicetta, C	1
Gnoni, R	1
Boni, C	1
Keskin, U	1
Ercan, CM	1
Yilmaz, A	1
Babacan, A	1
Korkmaz, C	1
Duru, NK	1
Ergun, A	1
García-Arpa, M	1
Lozano-Martín, E	1
Rodríguez, CR	1
Rodríguez-Vázquez, M	1
Barbie, TU	1
Ma, C	1
Margenthaler, JA	1
Metzger Filho, O	1
Mallon, E	2
Gusterson, B	1
Viale, G	3
Winer, EP	1
Thürlimann, B	2
Gelber, RD	2
Colleoni, M	3
Debled, M	1
Price, KN	2
Regan, MM	1
Coates, AS	2
Goldhirsch, A	3
Munzone, E	1
Gusterson, BA	1
MacGrogan, G	1
Bibeau, F	1
Lelkaitis, G	1
Tan, WW	1
Allred, JB	1
Moreno-Aspitia, A	1
Northfelt, DW	1
Ingle, JN	1
Goetz, MP	1
Perez, EA	1
Sansone, P	1
Ceccarelli, C	1
Berishaj, M	1
Chang, Q	1
Rajasekhar, VK	1
Perna, F	1
Bowman, RL	1
Vidone, M	1
Daly, L	1
Nnoli, J	1
Santini, D	1
Taffurelli, M	1
Shih, NN	1
Feldman, M	1
Mao, JJ	1
Colameco, C	1
Chen, J	1
DeMichele, A	1
Fabbri, N	1
Healey, JH	1
Cricca, M	1
Gasparre, G	1
Lyden, D	1
Bonafé, M	1
Bromberg, J	1
Yamamoto, D	1
Yamamoto, C	1
Yamamoto, M	1
Glaser, RL	1
York, AE	1
Dimitrakakis, C	1
Lanitis, S	1
Sivakumar, S	1
Behranwala, K	1
Zacharakis, E	1
Al Mufti, R	1
Hadjiminas, DJ	1
Olson, JA	1
Budd, GT	1
Carey, LA	1
Harris, LA	1
Esserman, LJ	1
Fleming, GF	1
Marcom, PK	1
Leight, GS	1
Giuntoli, T	1
Commean, P	1
Bae, K	1
Luo, J	1
Ellis, MJ	1
Lipsitz, M	1
Delea, TE	1
Guo, A	1
Ichinose, Y	1
Kobayashi, T	1
Fujimoto, A	1
Uchida, S	1
Sasaoki, T	1
Goto, K	1
Torrisi, R	1
Bagnardi, V	1
Rotmensz, N	1
Scarano, E	1
Iorfida, M	1
Veronesi, P	1
Luini, A	1
Santoro, A	1
Kusama, M	1
Ni, YB	1
Yang, WJ	1
Bu, H	1
Zheng, H	1
Lambertini, M	1
Pronzato, P	1
Giraudi, S	1
Levaggi, A	1
Bighin, C	1
Del Mastro, L	1
Chanplakorn, N	1
Chanplakorn, P	1
Suzuki, T	1
Ono, K	1
Wang, L	1
Chan, MS	1
Wing, L	1
Yiu, CC	1
Chow, LW	2
Sasano, H	1
Novoa Vargas, A	1
Font López, KC	1
Amador, DD	1
Wink, CJ	1
Woensdregt, K	1
Nieuwenhuijzen, GA	1
van der Sangen, MJ	1
Hutschemaekers, S	1
Roukema, JA	1
Tjan-Heijnen, VC	1
Voogd, AC	1
Hata, K	1
Hirai, I	1
Tanaka, T	1
Tanino, H	1
Alkaied, H	1
Harris, K	1
Brenner, A	1
Awasum, M	1
Varma, S	1
Sasaki, Y	1
Okuyama, M	1
Hibino, M	1
Tenma, K	1
Nakamura, M	1
Li, J	1
Xu, BH	1
Wang, JY	1
Li, Q	2
Zhang, P	1
Yuan, P	1
Ma, F	1
Fan, Y	1
Cai, RG	1
Zabolotny, BP	1
Zalai, CV	1
Meterissian, SH	1
Chia, WK	1
Lim, YL	1
Greaves, MW	1
Ang, P	1
Maciá Escalante, S	1
Pons Sanz, V	1
Rodríguez Lescure, A	1
Ballester Navarro, I	1
Carrato Mena, A	1
Giordano, SH	1
Hortobagyi, GN	1
Kennecke, HF	1
Olivotto, IA	1
Speers, C	1
Norris, B	1
Chia, SK	1
Bryce, C	1
Gelmon, KA	1
Arriola, E	1
Hui, E	1
Dowsett, M	1
Smith, IE	1
Yip, AY	1
Loo, WT	1
Toi, M	1
Krainick-Strobel, UE	1
Lichtenegger, W	1
Wallwiener, D	1
Tulusan, AH	1
Jänicke, F	1
Bastert, G	1
Kiesel, L	1
Wackwitz, B	1
Paepke, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.[NCT00908531]	Phase 3	123 participants (Actual)	Interventional	2009-05-31	Terminated (stopped due to Poor recruitement)
PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study[NCT02411344]	Phase 2	64 participants (Actual)	Interventional	2014-02-28	Completed
A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205]	Phase 3	8,028 participants (Actual)	Interventional	1998-03-31	Completed
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer[NCT01105312]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2010-09-30	Completed
Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate [NCT00535418]	Phase 2/Phase 3	35 participants (Actual)	Interventional	2000-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Clinical benefit rate will be estimated by the total number of patients with an objective status of CR, PR, or SD for duration of at least 6 months divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculated. (NCT01105312)
Timeframe: from baseline up to 6 months

Confirmed Response Rate (Phase I)

Intervention	percentage of participants (Number)
Phase II	0

A confirmed response is defined to be a CR or PR (as determined by RECIST criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. The number of confirmed responses will be reported here. (NCT01105312)
Timeframe: from baseline up to 5 years

Duration of Response (Phase II)

Intervention	Participants (Count of Participants)
Phase I: Dose Level One	0
Phase I: Dose Level Two	2

Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 5 years post-registration

Maximum-tolerated Dose (Phase I)

Intervention	months (Median)
Phase II	NA

MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6> new patients). If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT are seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. The number of DLT's will be reported here. (NCT01105312)
Timeframe: Up to 2.5 months

Progression-free Survival (Phase II)

Intervention	Participants (Count of Participants)
Phase I: Dose Level One	1
Phase I: Dose Level Two	3

Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. PFS at 6 months will be estimated. The distribution of PFS will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 6 months

Response Rate (Phase II)

Intervention	months (Median)
Phase II	2.1

"A confirmed response is defined to be a CR or PR (as determined by RECIST (version 1.1 criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.~A CR is defined as:~All of the following must be true:~Disappearance of all non-nodal target lesions~Each target lymph node must have reduction in short axis to <1.0 cm~A PR is defined as:~At least a 30% decrease in the sum of the longest diameters of the non-nodal target lesions and the short axes of the target lymph nodes taking as reference the BSD (Section 11.41)" (NCT01105312)
Timeframe: from baseline up to 5 years post-registration

Survival Time (Phase II)

Intervention	percentage of participants (Number)
Phase II	0

Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration

Time to Treatment Failure

Intervention	months (Median)
Phase II	16.1

Time to treatment failure (TTF) is defined as the time from the date of registration to the date at which the patient is removed from treatment due to progression, unacceptable adverse events, or refusal. The distribution of TTF will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration

Time-to-disease Progression (Phase II)

Intervention	months (Median)
Phase II	2

"Time-to-disease progression (TTP) is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of TTP will be estimated using the method of Kaplan-Meier. Progression is defined as at least one of the following:~At least one new malignant lesion or a lymph node whose short axis has increased to >1.5 cm~At least a 20% increase in the sum of diameters of target lesions taking as reference the MSD. In addition, the sum must also demonstrate an absolute increase of at least 0.5 cm" (NCT01105312)
Timeframe: from baseline up to 6 months

Article	Year
Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. Journal of cutaneous pathology, 2020, Volume: 47, Issue:7 Topics: Aged; Antibodies, Antinuclear; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; F	2020
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. JPMA. The Journal of the Pakistan Medical Association, 2014, Volume: 64, Issue:7 Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; H	2014
Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review. Clinical breast cancer, 2012, Volume: 12, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom	2012
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. Journal of surgical oncology, 2005, Apr-01, Volume: 90, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms	2005

Article	Year
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast cancer research : BCR, 2020, 05-14, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct	2020
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 2018, 01-01, Volume: 110, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcin	2018
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:1 Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Denmark;	2018
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:1 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms	2018
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 06-01, Volume: 30, Issue:6 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro	2019
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Sep-01, Volume: 33, Issue:25 Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In	2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal	2015
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clinical breast cancer, 2016, Volume: 16, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor	2016
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. Journal of the American College of Surgeons, 2009, Volume: 208, Issue:5 Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinom	2009
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Hormones & cancer, 2011, Volume: 2, Issue:1 Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplas	2011
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. Ginecologia y obstetricia de Mexico, 2011, Volume: 79, Issue:9 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modalit	2011
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer letters, 2008, Apr-18, Volume: 262, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neopl	2008
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC cancer, 2008, Feb-26, Volume: 8 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, D	2008

Article	Year
De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 04-20, Volume: 38, Issue:12 Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Humans; Letroz	2020
Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. Medicine, 2021, Apr-09, Volume: 100, Issue:14 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female;	2021
Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial. Bulletin of the American College of Surgeons, 2017, Volume: 102, Issue:1 Topics: Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; C	2017
[A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Duct	2018
Paraneoplastic syndrome - a rare but treatable cause of non-thyroid-related extraocular muscle enlargement. Orbit (Amsterdam, Netherlands), 2019, Volume: 38, Issue:6 Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duc	2019
Hormone Receptor-Positive Breast Cancer Choroidal Infiltrates before and after Systemic Aromatase Inhibitor Therapy. Ophthalmology, 2019, Volume: 126, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Female; Human	2019
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast cancer research and treatment, 2013, Volume: 141, Issue:1 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh	2013
[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:13 Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Human	2013
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:12 Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms	2013
Radiation recall reaction with letrozole therapy in breast cancer. Clinical breast cancer, 2014, Volume: 14, Issue:3 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole;	2014
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Annals of surgical oncology, 2014, Volume: 21, Issue:5 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo	2014
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report. Clinical breast cancer, 2014, Volume: 14, Issue:5 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocr	2014
Morphea following radiation therapy in a patient with breast cancer. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Combi	2015
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. Annals of surgical oncology, 2015, Volume: 22, Issue:12 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;	2015
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature communications, 2016, Feb-09, Volume: 7 Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal;	2016
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; E	2016
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:7 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Implants; Breast Neoplasms; Carcin	2017
A case of Meigs syndrome mimicking metastatic breast carcinoma. World journal of surgical oncology, 2009, Jan-22, Volume: 7 Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Diffe	2009
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Current medical research and opinion, 2010, Volume: 26, Issue:10 Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit	2010
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:13 Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino	2010
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast cancer research and treatment, 2011, Volume: 126, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast;	2011
[A case of secondary inflammatory breast cancer with multiple metastases in which operation was possible through letrozole monotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Ductal, Breast; Catheter Ablation; Combined Modali	2011
[Significance of HER2 testing in breast cancer]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2011, Volume: 40, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms;	2011
Letrozole withdrawal response in locally advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hepacivirus; Humans	2011
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. Annals of surgical oncology, 2012, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla	2012
[A case of liver metastasis of breast cancer responding to letrozole]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole;	2012
[A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:6 Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Femal	2012
[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:5 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Ductal, Breast; Chem	2012
Toxic epidermal necrolysis in patient with breast cancer receiving letrozole. The Lancet. Oncology, 2006, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Fatal Outcome; Female; Humans; L	2006
Primary hormone treatment in postmenopausal women with breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast	2006
Leuprolide acetate plus aromatase inhibition for male breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P	2006
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Br	2007
Aromatase inhibitors and male breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:3 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Br	2007

letrozole and Carcinoma, Ductal, Breast